Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE ...

Caribou delays readout, discontinues programs, betting on off-the-shelf CAR-T therapies. Once valued at $700 million, the company today is worth $78 million . Manage alerts for this article; ...